Skip to main content
OpenTrials

Clinical trial condition

Hematological Malignancies

Explore clinical trials studying Hematological Malignancies. Study availability and eligibility vary by location and protocol.

98 public trials 21 recruiting studies
Refine in advanced search Browse all conditions

Hematological Malignancies trial results

Completed

Compassionate Use Study of Tenalisib (RP6530)

NCT03711604

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +3 more
Locations
  • University of California, Hellen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • Division of Hematology, University of Colorado, Denver, Colorado, United States
  • Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Completed

Dose-range Finding Treosulfan-based Conditioning

NCT01063647

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +3 more
Locations
  • Helsinki University Central Hospital Helsinki, Finland
  • Charité University Hospital Berlin Berlin, Germany
  • University Hospital Hamburg Eppendorf Hamburg, Germany
  • 5th Medical Clinic, Clinic North Nuremberg, Germany
View Trial Details
Completed

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

NCT01607892

Conditions
Blood Protein Disorders, Bone Marrow Diseases, Cardiovascular Diseases, +35 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
View Trial Details
Completed

Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings

NCT00603954

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +3 more
Locations
  • AZ Gasthuisberg Leuven Leuven, Flamish Brabant, Belgium
  • UZ Gent Ghent, Flanders Oost, Belgium
  • University Hospital Mont-Godinne Godinne, Namur, Belgium
  • AZ St-Jan Bruges, West Flanders, Belgium
View Trial Details
Completed

Pasireotide in Prevention of GI Toxicity

NCT02215070

Conditions
Bone Marrow Diseases, Chronic Disease, Disease Attributes, +22 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Duke University Medical Center Durham, North Carolina, United States
View Trial Details

Related conditions